FDC reported a consolidated net profit of ₹1,324.9 million for the quarter ended June 30, 2026, marking an 8% increase from ₹1,213.5 million in the corresponding period of the previous year. Revenue from operations grew to ₹6,676.9 million, up from ₹6,484.1 million year-on-year, driven by steady performance in its pharmaceutical segment. In a separate strategic move, the Board of Directors granted in-principle approval to invest up to ₹4.5 million for a minimum 26% equity stake in Netra Green Energy Private Limited, a subsidiary of Sunsare Energy Private Limited, to support power procurement for its API manufacturing plant at Roha.

The financial results were reviewed by statutory auditors B S R & Co. LLP and approved by the Board on August 5, 2026, pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The standalone net profit stood at ₹1,320.2 million, compared to ₹1,222.0 million in Q1FY25. Basic and diluted earnings per share (EPS) rose to ₹8.14 on a consolidated basis and ₹8.11 on a standalone basis, reflecting improved profitability despite margin pressures.

Financial Performance Highlights

FDC’s top-line growth was accompanied by a slight contraction in EBITDA margins, indicating cost management challenges amidst rising input expenses. Consolidated EBITDA increased to approximately ₹1,430 million (derived from profit before tax and tax expense adjustments) but saw margin compression. The company operates exclusively in the pharmaceuticals segment, with revenues generated primarily through its domestic and international subsidiaries.

On a standalone basis, revenue from operations was ₹6,551.0 million, up from ₹6,422.8 million year-on-year. Other income contributed ₹4,734 million to standalone total income, while consolidated other income stood at ₹4,766 million. Finance costs remained low at ₹83 million (consolidated), showing effective debt management.

Strategic Investment in Green Energy

The Board’s approval to acquire a stake in Netra Green Energy is part of FDC’s broader sustainability strategy. The investment, capped at ₹4.5 million, will be made in one or more tranches subject to due diligence and regulatory approvals. This move aims to secure power procurement under the Group Captive Solar Project for the company’s API manufacturing facility in Roha, potentially reducing long-term energy costs and carbon footprint.

Analytical Observations

While revenue growth remains robust, the divergence between revenue growth (3.0%) and profit growth (9.2%) suggests operational leverage or favorable mix shifts. However, the marginal decline in EBITDA margins warrants monitoring as input costs remain volatile. The company continues to monitor regulatory changes impacting employee benefit obligations, having recognized a non-recurring exceptional item of ₹2,079 million in FY26 due to actuarial valuation changes under Ind AS 19. No such impact was recorded in Q1FY26.

Auditor’s Note

B S R & Co. LLP, the statutory auditors, issued an unmodified review conclusion on both standalone and consolidated results. The audit report highlights that quarterly figures may not be directly additive to year-to-date numbers due to fair value adjustments recognized under Ind AS 109. Additionally, interim financial information from three wholly-owned subsidiaries—FDC International Limited (UK), FDC Inc. (USA), and Fair Deal Corporation Pharmaceuticals SA (South Africa)—was not reviewed but deemed immaterial to the group.

Food Safety Officials from the Food & Drug Administration (FDA), Maharashtra, visited FDC Limited depots in Chhatrapati Sambhaji Nagar and Nagpur on June 3, 2026, seizing certain stock of the company's product 'Enerzal' and collecting samples for examination regarding alleged misbranding. The company stated that the final examination order is pending and it will take appropriate legal recourse, while business operations continue as usual.

Regulatory Action

The FDA's action involves the seizure of stock and the collection of samples for examination. According to the disclosure, the inspection relates to the alleged misbranding of the product. The company received the communication regarding this action on June 3, 2026. As of the filing date, the final examination order is yet to be received.

Company Response

FDC Limited stated that there is no material financial impact on the company or its operations as of the current date. The company has indicated its intent to pursue appropriate legal recourse in response to the regulatory action. Stakeholders are advised to await further official communication regarding the outcome of the examination.